文章摘要
钟 融,吴雪卿,瞿文超,高晴倩,谢 璐,孙佳晔.乳癌术后方对乳腺癌术后患者生活质量、肿瘤标志物和外周血T细胞亚群的影响[J].,2022,(6):1064-1068
乳癌术后方对乳腺癌术后患者生活质量、肿瘤标志物和外周血T细胞亚群的影响
Effect of Breast Cancer Postoperative Prescription on Quality of Life, Tumor Markers and Peripheral Blood T Lymphocyte Subsets in Patients with Breast Cancer after Operation
投稿时间:2021-08-26  修订日期:2021-09-21
DOI:10.13241/j.cnki.pmb.2022.06.014
中文关键词: 乳癌术后方  乳腺癌  术后  生活质量  肿瘤标志物  外周血T细胞亚群
英文关键词: Breast cancer postoperative prescription  Breast cancer  After operation  Quality of life  Tumor markers  Peripheral blood T cell subsets
基金项目:上海市科学技术委员会科研计划项目(19401934000)
作者单位E-mail
钟 融 上海中医药大学附属曙光医院中医乳腺外科 上海 200021 zhongrong19dr@163.com 
吴雪卿 上海中医药大学附属曙光医院中医乳腺外科 上海 200021  
瞿文超 上海中医药大学附属曙光医院中医乳腺外科 上海 200021  
高晴倩 上海中医药大学附属曙光医院中医乳腺外科 上海 200021  
谢 璐 上海中医药大学附属曙光医院中医乳腺外科 上海 200021  
孙佳晔 上海中医药大学附属曙光医院中医乳腺外科 上海 200021  
摘要点击次数: 19
全文下载次数: 16
中文摘要:
      摘要 目的:观察乳癌术后方对乳腺癌术后患者生活质量、肿瘤标志物和外周血T细胞亚群的影响。方法:选择2017年6月~2018年6月期间我院收治的乳腺癌术后长期门诊随访患者100例,根据双色球法将患者分为对照组(50例)和实验组(50例),对照组接受西医常规标准化治疗,实验组在此基础上于术后接受乳癌术后方治疗,治疗1年后对比两组疗效、生活质量、肿瘤标志物、外周血T细胞亚群和3年无病生存率。结果:实验组的临床总有效率为84.00%(42/50),效果优于对照组的56.00%(28/50),组间比较有统计学差异(P<0.05)。治疗后,实验组症状领域评分较对照组低,总体健康状况、功能领域评分高于对照组(P<0.05)。治疗后,实验组血清糖类抗原125(CA125)、癌胚抗原(CEA)、恶性肿瘤特异性生长因子(TSGF)水平低于对照组(P<0.05)。与对照组比较,治疗后实验组CD3+、CD4+、CD4+/CD8+较高,CD8+较低(P<0.05)。实验组的3年无病生存率高于对照组(P<0.05)。结论:乳腺癌术后患者在西医常规标准化治疗基础上添加乳癌术后方,效果较好,可有效控制癌症,提高机体免疫功能,促进生活质量改善,提高3年无病生存率。
英文摘要:
      ABSTRACT Objective: To observe the effect of breast cancer postoperative prescription on the quality of life, tumor markers and peripheral blood T lymphocyte subsets in patients with breast cancer after operation. Methods: From June 2017 to June 2018, 100 patients who were admitted to our hospital with long-term outpatient follow-up with breast cancer after operation were selected, and they were divided into control group (50 cases) and experimental group (50 cases) according to the double chromosphere method. The control group received routine standardized treatment of Western medicine, and the experimental group after operation received breast cancer postoperative prescription treatment on this basis. 1 year after treatment, the efficacy, quality of life, tumor markers, peripheral blood T cell subsets and 3-year disease-free survival rate were compared between the two groups. Results: The total clinical effective rate in the experimental group was 84.00% (42/50), which was better than 56.00% (28/50) in the control group, there was significant difference between the groups(P<0.05). After treatment, the scores of symptom field were lower than those in the control group, and the scores of overall health status and functional field in the experimental group were higher than those in the control group (P<0.05). After treatment, the levels of serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and tumor specific growth factor (TSGF) in the experimental group were lower than those in the control group(P<0.05). Compared with the control group, CD3+, CD4+, CD4+/CD8+ in the experimental group after treatment increased, and CD8+ decreased(P<0.05). The 3-year disease-free survival rate in the experimental group was higher than that in the control group(P<0.05). Conclusion: The patients with breast cancer after operation use breast cancer postoperative prescription on the basis of conventional standardized treatment has a good effect, which can effectively control cancer, improve immune function, promote the improvement of life quality, and improve the 3-year disease-free survival rate.
查看全文   查看/发表评论  下载PDF阅读器
关闭